Premium
Protection against cardiac hypertrophy by geniposide involves the GLP‐1 receptor / AMPKα signalling pathway
Author(s) -
Ma ZhenGuo,
Dai Jia,
Zhang WenBin,
Yuan Yuan,
Liao HaiHan,
Zhang Ning,
Bian ZhouYan,
Tang QiZhu
Publication year - 2016
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.13449
Subject(s) - ampk , endocrinology , muscle hypertrophy , chemistry , medicine , isoprenaline , agonist , protein kinase a , endoplasmic reticulum , receptor , pharmacology , microbiology and biotechnology , kinase , stimulation , biology , biochemistry
Background and Purpose Activation of glucagon‐like peptide‐1 (GLP‐1) receptor exerts a range of cardioprotective effects. Geniposide is an agonist of GLP‐1 receptor, but its role in cardiac hypertrophy remains completely unknown. Here, we have investigated its protective effects and clarified the underlying molecular mechanisms. Experimental Approach The transverse aorta was constricted in C57/B6 mice and then geniposide was given orally for 7 weeks. Morphological changes, echocardiographic parameters, histological analyses and hypertrophic markers were used to evaluate hypertrophy. Key Results Geniposide inhibited the hypertrophic response induced by constriction of the transverse aorta or by isoprenaline. Activation of 5′‐AMP‐activated protein kinase‐α (AMPKα) and inhibition of mammalian target of rapamycin, ERK and endoplasmic reticulum stress were observed in hypertrophic hearts that were treated with geniposide. Furthermore, Compound C (CpC) or knock‐down of AMPKα restricted protection of geniposide against cell hypertrophy and activation of mammalian target of rapamycin and ERK induced by hypertrophic stimuli. CpC or shAMPKα also abolished the protection of geniposide against endoplasmic reticulum stress induced by thapsigargin or dihtiothreitol. The cardio‐protective effects of geniposide were ablated in mice subjected to CpC. GLP‐1receptor blockade counteracted the anti‐hypertrophic response and activation of AMPKα by geniposide. Knock‐down of GLP‐1 receptor also offset the inhibitory effects of geniposide on cardiac hypertrophy in vivo . Conclusions and Implications Geniposide protected against cardiac hypertrophy via activation of the GLP‐1 receptor/AMPKα pathway. Geniposide is a potential therapeutic drug for cardiac hypertrophy.